BR112016029761A8 - composições compreendendo um derivado de ácido quinolona carboxílico e agentes efervescentes, uso das mesmas e forma cristalina do referido derivado - Google Patents

composições compreendendo um derivado de ácido quinolona carboxílico e agentes efervescentes, uso das mesmas e forma cristalina do referido derivado

Info

Publication number
BR112016029761A8
BR112016029761A8 BR112016029761A BR112016029761A BR112016029761A8 BR 112016029761 A8 BR112016029761 A8 BR 112016029761A8 BR 112016029761 A BR112016029761 A BR 112016029761A BR 112016029761 A BR112016029761 A BR 112016029761A BR 112016029761 A8 BR112016029761 A8 BR 112016029761A8
Authority
BR
Brazil
Prior art keywords
compositions
derivative
carboxylic acid
quinolone carboxylic
crystalline form
Prior art date
Application number
BR112016029761A
Other languages
English (en)
Other versions
BR112016029761B1 (pt
BR112016029761A2 (pt
Inventor
Li Danping
Original Assignee
Melinta Subsidiary Corp
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54868661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016029761(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Subsidiary Corp, Melinta Therapeutics Inc filed Critical Melinta Subsidiary Corp
Publication of BR112016029761A2 publication Critical patent/BR112016029761A2/pt
Publication of BR112016029761A8 publication Critical patent/BR112016029761A8/pt
Publication of BR112016029761B1 publication Critical patent/BR112016029761B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

composições antimicrobianas com agentes efervescentes. a presente invenção refere-se a composições farmacêuticas compreendendo um derivado de ácido carboxílico de quinolona como agente antimicrobiano e um agente efervescente. estas composições têm tolerabilidade gastrointestinal melhorada e/ou potencial reduzido para causar efeitos colaterais gastrointestinais. estas composições são úteis para administração oral, para tratar, prevenir, ou reduzir o risco de infecções microbianas.
BR112016029761-0A 2014-06-20 2015-06-19 Composições compreendendo um derivado de ácido quinolona carboxílico e agentes efervescentes e uso das mesmas BR112016029761B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462014786P 2014-06-20 2014-06-20
US62/014,786 2014-06-20
PCT/US2015/036605 WO2015196027A1 (en) 2014-06-20 2015-06-19 Antimicrobial compositions with effervescent agents

Publications (3)

Publication Number Publication Date
BR112016029761A2 BR112016029761A2 (pt) 2017-08-22
BR112016029761A8 true BR112016029761A8 (pt) 2021-06-29
BR112016029761B1 BR112016029761B1 (pt) 2023-03-07

Family

ID=54868661

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029761-0A BR112016029761B1 (pt) 2014-06-20 2015-06-19 Composições compreendendo um derivado de ácido quinolona carboxílico e agentes efervescentes e uso das mesmas

Country Status (31)

Country Link
US (2) US20150366857A1 (pt)
EP (3) EP3919057A1 (pt)
JP (2) JP6995479B2 (pt)
CN (2) CN114831955B (pt)
AR (1) AR100920A1 (pt)
AU (3) AU2015276954B2 (pt)
BR (1) BR112016029761B1 (pt)
CA (1) CA2952950C (pt)
CL (2) CL2016003273A1 (pt)
CR (2) CR20160592A (pt)
CY (2) CY1121995T1 (pt)
DK (2) DK3581180T3 (pt)
EA (1) EA034152B1 (pt)
EC (1) ECSP16095540A (pt)
ES (2) ES2732865T3 (pt)
HR (2) HRP20211685T1 (pt)
HU (2) HUE044764T2 (pt)
IL (1) IL249622A0 (pt)
LT (2) LT3581180T (pt)
MX (2) MX368940B (pt)
PE (2) PE20170304A1 (pt)
PH (1) PH12016502548A1 (pt)
PL (2) PL3581180T3 (pt)
PT (2) PT3157510T (pt)
RS (2) RS59064B1 (pt)
SI (2) SI3581180T1 (pt)
SV (1) SV2016005349A (pt)
TR (1) TR201909417T4 (pt)
TW (2) TWI705814B (pt)
UY (1) UY36184A (pt)
WO (1) WO2015196027A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022240897A1 (en) * 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194617A (en) * 1988-12-17 1993-03-16 Meiji Seika Kaisha, Ltd. 2,3-disubstituted-4-hydroxyquinoline derivatives
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
RU2177945C1 (ru) 1995-09-22 2002-01-10 Вакунага Фармасьютикал КО., Лтд. Производное пиридонкарбоновой кислоты или его соль
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
DE19814256A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Feste, schnellzerfallende Cetirizin-Formulierungen
PL346798A1 (en) 1998-09-14 2002-02-25 Ranbaxy Lab Ltd Orally administered controlled drug delivery system providing temporal and spatial control
US6187317B1 (en) * 1999-07-14 2001-02-13 Judith Taylor Natural anti-diarrheal composition and method
US6414036B1 (en) * 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
JP2005097116A (ja) 1999-11-11 2005-04-14 Wakunaga Pharmaceut Co Ltd キノリンカルボン酸誘導体アルカリ金属塩及びこれを用いたキノリンカルボン酸誘導体の精製法
WO2003101431A1 (en) * 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
JP5274012B2 (ja) 2004-07-30 2013-08-28 アボット・ラボラトリーズ ピリドンカルボン酸抗菌薬の調製
EP3056492B1 (en) 2004-10-08 2021-09-22 AbbVie Inc. Meglumine salt and crystalline forms thereof of a drug (delafloxacin)
EP2377557B1 (en) * 2004-11-24 2016-10-26 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP5284777B2 (ja) 2005-04-11 2013-09-11 アボット・ラボラトリーズ 難溶性薬剤の改善された溶解プロファイルを有する医薬組成物
DE602005007205D1 (de) 2005-07-19 2008-07-10 Ethypharm Sa Gastroretentive Zusammensetzungen und Verfahren zur Herstellung
US7611739B2 (en) 2006-01-06 2009-11-03 Amerilab Technologies, Inc. Method of using guava extract and composition including guava extract
US20080171158A1 (en) * 2006-08-11 2008-07-17 Aqua Resources Corporation Nanoplatelet copper hydroxides and methods of preparing same
CN1943561A (zh) * 2006-08-23 2007-04-11 北京阜康仁生物制药科技有限公司 普卢利沙星口腔崩解片及其制备方法
JP2010514702A (ja) 2006-12-22 2010-05-06 アイロンウッド ファーマシューティカルズ，インコーポレーテッド 食道障害の治療方法および治療用組成物
WO2008148798A2 (en) * 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CN104958296B (zh) * 2008-11-15 2017-12-01 麦林塔医疗有限公司 抗微生物组合物
WO2010096551A2 (en) 2009-02-18 2010-08-26 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions
GB201020076D0 (en) * 2010-11-26 2011-01-12 Liverpool School Tropical Medicine Antimalarial compounds
AU2012205669B2 (en) * 2011-01-10 2015-08-20 Infinity Pharmaceuticals Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
KR101900249B1 (ko) * 2011-01-14 2018-11-02 스페로 트리넴, 인코포레이티드 자이라제 억제제 （ｒ）­１­에틸­３­［６­플루오로­５­［２­（１­하이드록시­１­메틸­에틸）피리미딘­５­일］­７­（테트라하이드로푸란­２­일）­１ｈ­벤즈이미다졸­２­일］우레아의 고체 형태
JP2013034468A (ja) * 2011-08-10 2013-02-21 Nisshin Sugar Mfg Co Ltd 発泡成型甘味料
WO2013090891A1 (en) * 2011-12-16 2013-06-20 Celanese Eva Performance Polymers, Inc. Controlled release vehicles having desired void volume architectures
CN102697751A (zh) * 2012-05-30 2012-10-03 河南牧翔动物药业有限公司 一种畜禽专用恩诺沙星泡腾分散片及其制备方法

Also Published As

Publication number Publication date
ES2732865T3 (es) 2019-11-26
EP3919057A1 (en) 2021-12-08
SI3581180T1 (sl) 2021-12-31
EP3157510B1 (en) 2019-03-27
CA2952950C (en) 2023-11-14
AU2020256457B2 (en) 2021-09-30
TW202005650A (zh) 2020-02-01
EP3581180A1 (en) 2019-12-18
TWI732337B (zh) 2021-07-01
HUE044764T2 (hu) 2019-11-28
CR20200565A (es) 2021-01-14
BR112016029761B1 (pt) 2023-03-07
NZ727638A (en) 2023-08-25
PT3581180T (pt) 2021-11-09
JP7149991B2 (ja) 2022-10-07
HRP20211685T1 (hr) 2022-02-04
JP2017518349A (ja) 2017-07-06
US20200237744A1 (en) 2020-07-30
MX2016017350A (es) 2017-04-06
CL2020003153A1 (es) 2021-06-25
CL2016003273A1 (es) 2017-08-04
DK3581180T3 (da) 2021-11-08
PE20170304A1 (es) 2017-04-19
EP3157510A4 (en) 2018-02-21
IL249622A0 (en) 2017-02-28
CN114831955B (zh) 2024-03-12
MX2019012608A (es) 2019-12-02
EA034152B1 (ru) 2020-01-09
AU2015276954B2 (en) 2020-07-23
LT3157510T (lt) 2019-09-25
WO2015196027A1 (en) 2015-12-23
AU2021286284A1 (en) 2022-01-06
CN106572982A (zh) 2017-04-19
HUE056298T2 (hu) 2022-02-28
US20150366857A1 (en) 2015-12-24
CY1121995T1 (el) 2020-10-14
AU2021286284B2 (en) 2024-02-29
EP3581180B1 (en) 2021-08-04
AU2015276954A1 (en) 2017-01-12
TWI705814B (zh) 2020-10-01
CN106572982B9 (zh) 2022-07-08
DK3157510T3 (da) 2019-07-01
CR20160592A (es) 2017-02-21
TR201909417T4 (tr) 2019-07-22
JP6995479B2 (ja) 2022-01-14
SI3157510T1 (sl) 2019-09-30
MX368940B (es) 2019-10-21
RS62538B1 (sr) 2021-12-31
SV2016005349A (es) 2017-08-31
JP2020183415A (ja) 2020-11-12
ECSP16095540A (es) 2017-03-31
AU2020256457A1 (en) 2020-11-12
PT3157510T (pt) 2019-06-21
PL3157510T3 (pl) 2019-12-31
AR100920A1 (es) 2016-11-09
BR112016029761A2 (pt) 2017-08-22
HRP20191133T1 (hr) 2019-09-20
LT3581180T (lt) 2021-12-27
TW201625249A (zh) 2016-07-16
PE20210927A1 (es) 2021-05-19
PH12016502548A1 (en) 2017-04-10
EA201692532A1 (ru) 2017-05-31
ES2897576T3 (es) 2022-03-01
CY1125395T1 (el) 2023-03-24
RS59064B1 (sr) 2019-08-30
CN114831955A (zh) 2022-08-02
UY36184A (es) 2016-01-29
PL3581180T3 (pl) 2022-02-07
EP3157510A1 (en) 2017-04-26
CA2952950A1 (en) 2015-12-23
CN106572982B (zh) 2022-06-03

Similar Documents

Publication Publication Date Title
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
BR112015027699A2 (pt) Uso de robenidina ou um sal terapeuticamente aceitável da mesma, composição farmacêutica antibacteriana e dispositivo médico
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MA43574A (fr) Compositions ayant des amplificateurs de perméation pour l'administration de médicaments
NI201500135A (es) Composición farmacéutica de hidrocloruro de s-ketamina
PH12016501988A1 (en) Antibacterial compounds
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
PH12018500358A1 (en) Compounds for use in an antibacterial applications
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2020003153A1 (es) Composiciones antimicrobianas con agentes efervescentes (divisional de solicitud n° 03273-2016)
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
EA201270547A1 (ru) Фармацевтическая композиция
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
MX360040B (es) Nuevo agente antibacteriano derivado de florfenicol unido a sulfoximina y el uso del mismo en el tratamiento de infecciones bacterianas en ganado vacuno.
BR112016024236A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
EA201692531A1 (ru) Способы лечения инфекций
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
UA91125U (uk) Антибактеріальна композиція
UA94988U (xx) Фармацевтична композиція
UA88315U (en) Antibacterial composition
EA201390764A1 (ru) Фармацевтические композиции
UA108238C2 (xx) Антибактеріальна композиція
TR201203083A2 (tr) Sefdinir ve klavulanik asit içeren farmasötik dozaj formu.
TR201203086A2 (tr) Sefiksim ve klavulanik asit içeren farmasötik dozaj formu.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MELINTA SUBSIDIARY CORP. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: MELINTA SUBSIDIARY CORP. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/06/2015, OBSERVADAS AS CONDICOES LEGAIS